Gene transfer and oncolytic viruses provide new therapeutic approaches for the treatment of hematologic malignancies. However, it is still too early to introduce gene delivery or oncolytic viruses into standard clinical protocol. It is very important to discuss the obstacles that gene transfer and oncolytic virotherapy face for the further clinical application for the treatment of hematologic malignancies, and updating the advances made to overcome them. The major concerns in this review include the approaches of the development of immuno-stimulatory gene transfer mediated-vaccination for leukemia therapy, RNAi-based therapy for leukemia and enhancement of sensitivity of target malignant cells to virotherapy and alteration of host immune response to favor oncolytic viruses. We conclude with a perspective on the future of the gene therapy and virotherapy for the treatment of hematologic malignancies, emphasizing the problems we should solve and the technological requirements for further clinical applications.
http://ift.tt/2ncyL9j
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
Ετικέτες
Παρασκευή 17 Μαρτίου 2017
Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
-
Summary 银屑病是一种常见的皮肤病,影响北欧国家大约 5‐10% 的人口和全世界超过 1.25 亿人。已证实此病与治疗依从性低(意味着人们不能坚持他们的治疗)、不健康的生活方式(例如抽烟、饮酒、体育活动减少)和因此而产生的代谢性疾病相关。银屑病患者中的抑郁频率更高,但关于...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου